Literature DB >> 15327832

Quantitative real time PCR of deoxycytidine kinase mRNA by Light Cycler PCR in relation to enzyme activity and gemcitabine sensitivity.

Jennifer Sigmond1, Judith R Kroep, Willem Loves, Giovanni Codacci-Pisanelli, Godefridus J Peters.   

Abstract

Deoxycytidine kinase (dCK) is essential for the phosphorylation of gemcitabine and can predict response to gemcitabine in vivo. Conventional Competitive Template-Reverse Transcriptase-Polymerase Chain Reaction (CT-RT-PCR) was correlated with real time PCR using a Light Cycler (LC) with SYBR-Green detection to enable rapid and sensitive detection of dCK mRNA expression. We used cDNA from human xenografts to establish a relation between dCK activity and gemcitabine sensitivity. A significant correlation of LC-PCR was found with CT-RT-PCR (Pearson: r = 0.956; P < 0.0001), enzyme activity (Pearson: r = 0.972; P = 0.003) and gemcitabine sensitivity (Pearson: r = 0.695; P = 0.048). The LC-PCR was also applied to needle biopsy specimens. In bladder tumors a similar correlation was found, while esophageal tumors with a high dCK expression responded to gemcitabine treatment. The LC is a rapid and reliable method for quantitation of dCK mRNA levels in tumors to predict clinical gemcitabine sensitivity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15327832     DOI: 10.1016/j.canlet.2004.04.016

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  5 in total

1.  Circulating bone morphogenetic protein 1-3 isoform increases renal fibrosis.

Authors:  Lovorka Grgurevic; Boris Macek; David R Healy; Amy L Brault; Igor Erjavec; Antonio Cipcic; Ivica Grgurevic; Dunja Rogic; Kresimir Galesic; Jelena Brkljacic; Ranka Stern-Padovan; Vishwas M Paralkar; Slobodan Vukicevic
Journal:  J Am Soc Nephrol       Date:  2011-03-17       Impact factor: 10.121

2.  Exogenous heparin binds and inhibits bone morphogenetic protein 6 biological activity.

Authors:  Jelena Brkljacic; Martina Pauk; Igor Erjavec; Antonio Cipcic; Lovorka Grgurevic; Renata Zadro; Gareth J Inman; Slobodan Vukicevic
Journal:  Int Orthop       Date:  2013-01-10       Impact factor: 3.075

3.  Noninvasive prediction of tumor responses to gemcitabine using positron emission tomography.

Authors:  Rachel E Laing; Martin A Walter; Dean O Campbell; Harvey R Herschman; Nagichettiar Satyamurthy; Michael E Phelps; Johannes Czernin; Owen N Witte; Caius G Radu
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-05       Impact factor: 11.205

4.  In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients.

Authors:  V Mey; E Giovannetti; F De Braud; S Nannizzi; G Curigliano; F Verweij; O De Cobelli; S Pece; M Del Tacca; R Danesi
Journal:  Br J Cancer       Date:  2006-07-25       Impact factor: 7.640

5.  Impact of cellular folate status and epidermal growth factor receptor expression on BCRP/ABCG2-mediated resistance to gefitinib and erlotinib.

Authors:  C Lemos; I Kathmann; E Giovannetti; C Calhau; G Jansen; G J Peters
Journal:  Br J Cancer       Date:  2009-03-10       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.